Monopar Therapeutics Inc.
Organization details
- Legal name
- Monopar Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Wilmette
- Headquarters state / province
- Illinois
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- MNPR
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001645469
- EIN
- 32-0463781
Board of directors
-
Arthur J. Klausner · DirectorSince 2023
-
Chandler Robinson · Director · Chief Executive OfficerSince 2023
-
Christopher M. Starr · DirectorSince 2023
-
Kim R. Tsuchimoto · Director · Chief Financial OfficerSince 2023
-
Lavina Talukdar · DirectorSince 2025
-
Michael J. Brown · DirectorSince 2023
-
Nicole Sweeny · DirectorSince 2026
-
Raymond Anderson · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 22, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
84.7%
-
87.2%
-
94.2%
-
98.7%
-
99.0%
Board connections
1 of this board's directors also sit on 1 other board.
- via Michael J. Brown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $104,925
- 1 purchase by 1 insider
- Sold, last 12 months
- $4,871,802
- 27 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 4, 2026 | Kim R. Tsuchimoto Director | Option exercise | +856 | $30.00 | $25,680 |
| Nov 4, 2026 | Kim R. Tsuchimoto Director | Option exercise | +2,035 | $14.00 | $28,490 |
| Nov 4, 2026 | Kim R. Tsuchimoto Director | Open-market sale | −1,295 | $70.75 | $91,621 |
| Nov 4, 2026 | Kim R. Tsuchimoto Director | Open-market sale | −996 | $71.35 | $71,065 |
| Nov 4, 2026 | Kim R. Tsuchimoto Director | Open-market sale | −600 | $72.21 | $43,326 |
| Nov 2, 2026 | Raymond Anderson Director | Option exercise | +1,402 | $30.00 | $42,058 |
| Nov 2, 2026 | Kim R. Tsuchimoto Director | Option exercise | +1,199 | $30.00 | $35,970 |
| Nov 2, 2026 | Raymond Anderson Director | Option exercise | +1,740 | $30.00 | $52,200 |
| Nov 2, 2026 | Kim R. Tsuchimoto Director | Open-market sale | −1,199 | $70.10 | $84,050 |
| Nov 2, 2026 | Raymond Anderson Director | Open-market sale | −840 | $66.16 | $55,574 |
| Nov 2, 2026 | Raymond Anderson Director | Open-market sale | −600 | $67.06 | $40,236 |
| Nov 2, 2026 | Raymond Anderson Director | Open-market sale | −200 | $68.68 | $13,736 |
| Nov 2, 2026 | Raymond Anderson Director | Open-market sale | −1,502 | $70.04 | $105,200 |
| Oct 20, 2026 | Chandler Robinson Director, Officer (Chief Executive Officer) | Shares withheld for tax | −597 | $92.59 | $55,276 |
| Oct 1, 2026 | Christopher M. Starr Director | Option exercise | +8,400 | $0.01 | $42 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Monopar Therapeutics Inc.
Who is the CEO of Monopar Therapeutics Inc.?
Chandler Robinson is Monopar Therapeutics Inc.'s Chief Executive Officer.
How many directors are on Monopar Therapeutics Inc.'s board?
Monopar Therapeutics Inc.'s board has 8 directors: Arthur J. Klausner, Chandler Robinson, Christopher M. Starr, Kim R. Tsuchimoto, Lavina Talukdar, Michael J. Brown, Nicole Sweeny and Raymond Anderson.
Are Monopar Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Monopar Therapeutics Inc. insiders bought $104,925 of shares in 1 purchase and sold $4.9 million of shares in 27 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="monopar-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.